0001728328 false A1 BC 0001728328 2022-12-15 2022-12-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 15, 2022

 

InMed Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

British Columbia 

  

001-39685 

  

98-1428279

(State or Other Jurisdiction
of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

Suite 310 – 815 W. Hastings Street

Vancouver, B.C.
Canada

  

V6C 1B4

(Address of Principal Executive Offices)   (Zip Code)

 

(Registrant’s Telephone Number, Including Area Code): (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07: Submission of Matters to a Vote of Security Holders.

 

On December 15, 2022, InMed Pharmaceuticals Inc., or the “Corporation”, held its Annual General Meeting of Shareholders. At the meeting, shareholders voted in favor of all items of business, as indicated below:

 

Proposal No. 1—Election of Directors

 

The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2023 Annual General Meeting of Shareholders:

 

Nominee  Votes For   % Votes For  

Votes

Withheld

   % Votes Withheld   Broker
Non-Votes		 
Eric A. Adams   159,223    94.90%   8,559    5.10%   179,813 
Andrew Hull   158,282    94.34%   9,500    5.66%   179,813 
Janet Grove   162,246    96.70%   5,536    3.30%   179,813 
Bryan Baldasare   160,764    95.82%   7,018    4.18%   179,813 
Nicole Lemerond   162,174    96.66%   5,608    3.34%   179,813 

 

Proposal No. 2—Appointment of Independent Registered Public Accounting Firm

 

The Corporation’s shareholders voted to approve the appointment of Marcum LLP as the independent registered public accounting firm of the Corporation until the 2023 Annual General Meeting of Shareholders or until a successor is named.

 

Votes For   % Votes For   Vote Against   % Votes Against   Abstain  

Broker
Non-Votes

 
 339,548    97,68%   0    0%   8,047    0 

 

Item 7.01 Regulation FD Disclosure.

 

On December 15, 2022, the Corporation issued a press release announcing the voting results of the meeting. A copy of the press release is furnished hereto as Exhibit 99.1.

 

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit 99.1   Press release, dated December 15, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 16, 2022

 

  INMED PHARMACEUTICALS INC.
   
  By: /s/ Eric A. Adams              
  Name:  Eric A. Adams
  Title: Chief Executive Officer

 

 

2
 

InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more InMed Pharmaceuticals Charts.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more InMed Pharmaceuticals Charts.